Biostax Corp. (OTCPK: BTAX)
Health Care · Biotechnology · US
$—
— today · — 1Y
Biostax Corp. (OTCPK: BTAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $21.65K and employs 4 people.
trading between 0.00 and 0.00.
Tweenvest scores Biostax Corp. across four factors: quality 13/100, value 20/100. Its strongest factor is value.
BTAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $21.65K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 108.24M
- Employees
- 4
- Next earnings
- —
About Biostax Corp.
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
- ISIN
- US45252A3059
- Listed since
- Aug 20, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Emergent Health CorpOTCPK: EMGE | $42.70K | $0.00 | — |
| Nascent Biotech, Inc.OTCPK: NBIO | $34.57K | $0.00 | +100.00% |
| Myrexis, Inc.OTCPK: MYRX | $27.58K | $0.00 | — |
| Burzynski Research Institute, Inc.OTCPK: BZYR | $26.29K | $0.00 | -89.74% |
| Carisma Therapeutics, Inc.OTCPK: CARM | $20.92K | $0.00 | -37.50% |
| Dragon Life Science Holdings Group, Inc.OTCPK: NOHO | $20.04K | $0.00 | — |
| T2 Biosystems, Inc.OTCPK: TTOO | $19.63K | $0.00 | +16.67% |
| Neovacs S.A.ENXTPA: ALNEV | $17.12K | €0.10 | -3.90% |
Figures last refreshed Oct 18, 2026.